{"id":8481,"date":"2022-07-12T14:26:19","date_gmt":"2022-07-12T13:26:19","guid":{"rendered":"https:\/\/science-nutrition.com\/?p=8481"},"modified":"2022-07-20T17:05:21","modified_gmt":"2022-07-20T16:05:21","slug":"the-safety-of-cannabidiol-as-a-novel-food-in-eu-data-gaps-and-uncertainties","status":"publish","type":"post","link":"https:\/\/science-nutrition.com\/en\/2022\/07\/12\/the-safety-of-cannabidiol-as-a-novel-food-in-eu-data-gaps-and-uncertainties\/","title":{"rendered":"The safety of cannabidiol as a Novel Food in EU: data gaps and uncertainties"},"content":{"rendered":"
\n

On 28 June 2022, a webinar information session was held to present the recently published EFSA \u201cStatement on safety of cannabidiol as a novel food: data gaps and uncertainties<\/a>\u201d to stakeholders.<\/em><\/p>\n

Indeed, 19 applications concerning cannabidiol (CBD) as Novel Food are under assessment at the EFSA level. While assessing these, it has become clear that there are knowledge gaps that need to be addressed before a conclusion on the safety of CBD can be reached by the EFSA Panel. Consequently, EFSA has issued this statement, summarising the state of knowledge on the safety of CBD consumption and highlighting areas where more data are needed. The available studies have some limitations: toxicological studies have been performed with varied mixtures\u00a0 and the content of other\u00a0 components and their identity are rarely described, the human studies have involved patients with concomitant use of medications; most data in humans refer to the efficacy of Epidyolex\u00ae, a CBD drug used to treat refractory epilepsies, at therapeutic doses at which adverse effects were sometimes observed. None \u201cNo Observed Adverse Effect Limit\u201d (NOAEL) could\u00a0 be identified from these studies. The session was focused on the explanation of the statement and covered the following aspects:<\/p>\n